Senores Pharmaceuticals has announced a board meeting to consider the financial results for the quarter and half-year.

The company has increased its stake in its US-based subsidiary, Havix Group Inc. (Aavis Pharmaceuticals), by acquiring 2.97% additional shares for USD 181 per share, raising its total holding to 73.04%. Havix’s turnover grew to USD 19.87 million in the latest fiscal year, reflecting strong growth over three years.

This move consolidates Senores’ control in its key US subsidiary, supporting its international expansion strategy.